Cytokinetics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Cytokinetics (CYTK) PT Lowered to $85 at Jefferies
May 23, 2024 5:59 AM EDTJefferies analyst Akash Tewari lowered the price target on Cytokinetics (NASDAQ: CYTK) to $85.00 (from $95.00) while maintaining a Buy rating.
The analyst comments "CYTK announced a $500m raise + amended its terms w/ Royalty Pharma (incl. updated royalty structure for afi, loan related to Ome... More



